Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Columns

Q&A column

April 2025
Q. Is it important to perform a manual differential on a CBC with a very low or very high mean corpuscular volume (MCV) result, or will a smear review/scan for RBC morphology suffice? Read answer.

Q. Do exact formalin fixation times and cold ischemia times have to be listed in the final pathology report for immunohistochemistry predictive marker testing so long as they are traceable on internal records (e.g. processor times, container label times)? Or is it sufficient to state that the formalin fixation and cold ischemia times meet ASCO/CAP recommendations of less than or equal to one hour cold ischemia time and greater than six hours but less than 72 hours formalin fixation time?

The only variable not in our final reports is our end of formalin time, but it is traceable through internal laboratory records. We document in the final report the time the tissue was removed from the body and the time it was placed in formalin. Then a blanket statement of “less than or equal to one hour cold ischemia time and greater than six but less than 72 hours formalin fixation time” is inserted in the comment when it applies. Read answer.

Newsbytes

April 2025—UPMC Enterprises has introduced Ahavi, a real-world data platform on which clinical researchers, data scientists, and developers of artificial intelligence can validate AI solutions before the University of Pittsburgh Medical Center deploys them. The platform provides de-identified real-world health care data from more than 80 University of Pittsburgh Medical Center sources. Comprehensive structured and unstructured data have been sourced from approximately 5 million patients across 24 hospitals in order to train and refine AI models and develop predictive analytics and clinical decision-making tools.

Put It on the Board

April 2025—The U.S. District Court for the Eastern District of Texas ruled on March 31 in favor of the laboratory plaintiffs in the two consolidated cases challenging the validity of the Food and Drug Administration’s final rule on laboratory-developed tests. The plaintiffs in the cases were the American Clinical Laboratory Association, Association for Molecular Pathology, HealthTrackRX and HealthTrackRX Indiana, and pathologist Michael Laposata, MD. The ruling by Judge Sean D. Jordan ordered that the plaintiffs’ motions for summary judgment be granted. The final rule that would have regulated LDTs as medical devices under the Federal Food, Drug and Cosmetic Act was vacated.

From the President’s Desk

March 2025—The number of payment and coverage challenges coming from private payers and being experienced by pathologists, our clinical labs, and our patients has exploded in recent years. The CAP has been tracking this increase closely and the problem seems to be getting worse by the month.

Clinical pathology selected abstracts

March 2025—Generative artificial intelligence is now readily available and has created a plethora of interest in health care, including in pathology and laboratory medicine. Unlike traditional AI, generative AI (Gen­AI) doesn’t rely solely on historical data to make predictions but instead uses patterns within historical data to create entirely new data. Excitement over Gen­AI must be weighed against the reality of maintaining human control over the technology and interpreting the data. The use of Gen­AI in health care may include not only streamlining administrative tasks but also performing safety critical clinical functions, such as image-based diagnosis. The risk-based approach and quality management of Gen­AI must be managed individually for each situation.

Anatomic pathology selected abstracts

March 2025—Invasive lobular carcinoma is characterized by loss of E-cadherin expression and CDH1 gene inactivation. The reliability and reproducibility of diagnosis for this tumor type is suboptimal and could be improved by better understanding the histomolecular and clinical heterogeneity of such tumors. The authors analyzed the relationship between the presence, type, or position of CDH1 mutations, E-cadherin expression, and clinicopathological features, including outcome, in a retrospective series of 251 primary invasive lobular carcinomas (ILC) with a median follow-up of 9.5 years. The mutational status of CDH1 (the gene encoding E-cadherin) was determined by RNA sequencing of frozen tumor samples. E-cadherin immunohistochemistry was performed with antibodies directed against the intracellular (clone 4A2C7) and extracellular (clone NCH38) domains.

Molecular pathology selected abstracts

March 2025—Genomic imprinting is an epigenetic process that results in expression of only one copy of a gene—either from a person’s mother or father—while the other parent’s copy of the same gene is silenced. A cluster of genes affected by imprinting on the proximal part of the long arm of chromosome 15 (15q11-q13) are associated with syndromic conditions. Deficient expression of the maternally inherited copy of UBE3A in this region results in Angelman syndrome, which is characterized by severe developmental delay, gait ataxia, and an apparent happy demeanor with profuse smiling, frequent laughing, and excitability. In contrast, deficient expression of paternally inherited genes in this region causes Prader-Willi syndrome. Clinical features of this condition can vary but often include developmental delay, short stature, hyperphagia, and obesity.

Newsbytes

March 2025—Delays while a courier is sent to the blood bank. Errors in judgment. Omission of steps in tracking who received a unit of blood. Wastage of blood product because clinicians were cautious and overordered or ordered too soon. Staffing issues. All of these potential blood bank-related problems can be mitigated with smart blood-storage devices, also called smart refrigerators or blood vending machines.

Q&A column

March 2025
Q. When should plasma mixing tests be performed in the coagulation laboratory, and how are they best interpreted? Read answer.

Q. How important is it for a laboratory to perform whole mount specimen collection and examination? Read answer.

Put It on the Board

March 2025—The Roche Tina-quant Lipoprotein (a) Gen.2 Molarity assay received 510(k) clearance from the Food and Drug Administration. It is the first 510(k)-cleared test of its kind available in the U.S. to measure lipoprotein(a) in nanomoles per liter. It will be broadly available on Cobas c analyzers. Lp(a) can vary in size and has no single, defined molecular weight. For this reason, Roche says, there is a consensus in the scientific community that Lp(a) levels should be measured in terms of the number of particles per liter of blood (nmol/L), rather than mass units (mg/dL), and that any conversion between mass and molar units is generally imprecise and unreliable. By using molar units, laboratory professionals and clinicians know the Lp(a) measurements reflect the number of particles rather than a difference in particle size.

MARKETPLACE

TRENDING